CD8A and neoplasm: Injection of MSN-MSR vaccine was able to locally enrich DC cells as well as deliver MSN co-loaded tumor antigen and TLR-9 receptor agonist to the recruited DC cells, inducing their activation and maturation, thus promoting massive infiltration of antigen-specific CD8+ T cells and IFN-γ+ CD8+ T cells, showing stronger tumor-suppressive effect than single MSR or MSN vaccine.